AU2018201307A1 — Neuroactive Steroid Formulations and Methods of Treating CNS Disorders
Assigned to Sage Therapeutics Inc · Expires 2018-03-15 · 8y expired
What this patent protects
Formulations comprising a neuroactive steroid, e.g., allopregnanolone; and optionally a cyclodextrin, e.g., a -cyclodextrin, e.g., a sulfo butyl ether P-cyclodextrin, e.g., a p-cyclodextrin, e.g., a sulfo butyl ether P-cyclodextrin, e.g., CAPTISOL@; and methods of use in treating…
USPTO Abstract
Formulations comprising a neuroactive steroid, e.g., allopregnanolone; and optionally a cyclodextrin, e.g., a -cyclodextrin, e.g., a sulfo butyl ether P-cyclodextrin, e.g., a p-cyclodextrin, e.g., a sulfo butyl ether P-cyclodextrin, e.g., CAPTISOL@; and methods of use in treating CNS disorders.
Drugs covered by this patent
- Zulresso (BREXANOLONE) · Sage Therap
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.